Image
Recommendation
Neoadjuvant endocrine therapy – Indications
Consider neoadjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer as an option to reduce tumour size if there is no definite indication for chemotherapy.
Consider neoadjuvant endocrine therapy for postmenopausal women with ER-positive invasive breast cancer as an option to reduce tumour size if there is no definite indication for chemotherapy
How this guidance was developed
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Consider") indicative of a conditional recommendation (using GRADE methods) by the source guideline authors. The source recommendation was accepted with no changes.
It is noted that ESO-ESMO 2017 and ESO-ESMO 2020 indicate that ‘Neoadjuvant ET should not be routinely recommended for young women outside of clinical trials’.
Related guidance by topic
Neoadjuvant endocrine therapy – Indications
Recommendation
Consider neoadjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer as an option to reduce tumour size if there is no definite indication for chemotherapy.
Principles in action
Safe and quality care
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Consider") indicative of a conditional recommendation (using GRADE methods) by the source guideline authors. The source recommendation was accepted with no changes.
It is noted that ESO-ESMO 2017 and ESO-ESMO 2020 indicate that ‘Neoadjuvant ET should not be routinely recommended for young women outside of clinical trials’.
Related guidance by topic
Image
